A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo-controlled, First-in-human Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Single Ascending Oral Doses Of Pf-06852231 Administered To Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 16 Feb 2018
Price : $35 *
At a glance
- Drugs PF-06852231 (Primary)
- Indications Neurological disorders
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 12 Feb 2018 Status changed from recruiting to completed.
- 16 Jan 2018 Planned End Date changed from 8 Mar 2018 to 1 Feb 2018.
- 16 Jan 2018 Planned primary completion date changed from 8 Mar 2018 to 1 Feb 2018.